AN2 Therapeutics Inc.

NASDAQ: ANTX · Real-Time Price · USD
1.06
-0.15 (-12.40%)
At close: May 30, 2025, 3:59 PM
1.10
3.77%
After-hours: May 30, 2025, 05:03 PM EDT

Company Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.

It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease.

The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics Inc.
AN2 Therapeutics Inc. logo
Country United States
IPO Date Mar 25, 2022
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Eric E. Easom

Contact Details

Address:
1800 El Camino Real
Menlo Park, California
United States
Website https://www.an2therapeutics.com

Stock Details

Ticker Symbol ANTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001880438
CUSIP Number 037326105
ISIN Number US0373261058
Employer ID 82-0606654
SIC Code 2834

Key Executives

Name Position
Eric E. Easom Co-Founder, Chief Executive Officer, President & Chairman of the Board
Joshua M. Eizen J.D. Chief Legal Officer, Chief Operating Officer & Corporate Secretary
Lucy O. Day CPA Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dr. George Harrison Talbot FACP, M.D. Co-Founder & Senior Clinical Advisor
Dr. Michael R. K. Alley Ph.D. Co-Founder, Senior Vice President of Research Fellow & Head of Biology
Dr. Sanjay Chanda Ph.D. Chief Development Officer
Dr. Stephen David Prior Ph.D. Chief Strategy Officer
Joseph S. Zakrzewski Co-Founder & Independent Chairman of the Board
Vince Hernandez Senior Vice President of Research & Head of Chemistry

Latest SEC Filings

Date Type Title
May 29, 2025 4 Filing
May 27, 2025 8-K Current Report
May 23, 2025 4 Filing
May 23, 2025 4 Filing
May 23, 2025 4 Filing
May 23, 2025 4 Filing
May 23, 2025 4 Filing
May 23, 2025 4 Filing
May 23, 2025 4 Filing
May 23, 2025 4 Filing